英国国家医疗服务体系（NHS）
- 英国国家医疗服务体系（NHS），National Health Service，它包括英格兰、苏格兰、威尔士国家健康服务体系。
- 国民保健服务提供了英格兰大部分的医疗保健 ,包括初级保健、住院服务,长期医疗、眼科和牙科。国家健康服务法案（1946年 ）在1948年7月5日生效。
- 英国国家医疗服务体系NHS，遵行救济贫民的选择性原则，并提倡了普遍性原则。凡有收入的英国公民都必须参加社会保险，按统一的标准缴纳保险费，按统一的标准享受有关福利，而不问收入多少，福利系统由政府统一管理实行。
项目背景情况
- 肺癌在英国、全球高发(2012年全球新增肺癌病例180万，死亡人数159万)
- 肺癌很难在早期发现，早期基本没有临床症状
- 基于以上原因，2012年苏格兰政府出资开展七种肺癌自身抗体筛查项目(The ECLS Study)
Lung cancer kills more people than any other cancer worldwide, with over 1.5 million deaths globally in 2012. In Scotland, nearly 5,000 people die from lung cancer every year.
It is often hard to find lung cancer early. Most people with early lung cancer do not have any symptoms, so only a small number of lung cancers are found at an early stage when treatment can be most successful. It is for this reason that the Scottish Government is co-‐funding the Early Cancer Detection test – Lung cancer Scotland (ECLS) Study along with Oncimmune Ltd, the company which developed EarlyCDT-‐ Lung -‐ the test being trialed in the study. This blood test, EarlyCDT-‐Lung, may be able to pick up very small lung cancers before they cause health problems.
ECLS Study项目介绍
- 项目名称：ECLS肺癌筛查项目
- 项目起始时间：2012年-2018 年
- 资金：苏格兰政府与Oncimmune公司共同出资
- 筛查人数：10000人(目前已经扩大到12000人)
项目意义：这是全球最大的基于血液肺癌筛查项目，这个研究的结果会让英国NHS决定是否将肺癌七种自身抗体检测在英国全国范围内政府推进开展。
The Study originally invited 10,000 high-‐risk people from Tayside, Glasgow and the surrounding areas to participate. It is planned that an extra 2,000 patients will now be recruited and some of these will come from Lanarkshire. These regions have been chosen because lung cancer is more common in these areas. Those who agree to take part in the Study either receive an EarlyCDT-‐Lung test or are followed up by usual care. Participants with a positive test are offered a chest X-‐ray and a series of CT scans over two years. All participants requiring further investigations or treatment are treated within NHS guidelines.
Early Cancer detection test – Lung cancer Scotland 
ECLS Brochure
ECLS Study
We would like to invite you to take part in a research study for a new blood test which may help find lung cancer earlier. The study will take place in Lanarkshire, Tayside and Greater Glasgow and Clyde areas. Click here for more information
UPDATE: Sir Alex Ferguson Supports Lung Cancer Campaign. Read More
The study has reached its 12,000 participant target.
This would not have been possible without volunteer contribution – THANK YOU!
The initials study results will be available on the website August 2019.
We are no longer recruiting for the study.
For more nformation:http://www.eclsstudy.org/home
A key outcome of this study will be the cost-‐effectiveness of screening high-‐risk patients with EarlyCDT-‐Lung. Although the first statistically powered results will be published in 2018 or 2019 the ECLS study wants to find out if earlier detection saves lives in the long term by following everyone who takes part in the study for up to 10 years. The Study will also seek patients’ feedback about the test so that this can be included as part of the decision about whether to offer it as a nationwide lung cancer-‐screening test.
ECLS Study项目进展（第一阶段）
筛查试验组 对照组
一组肺癌自身抗体谱筛查 常规诊疗
- 该研究英国NHS（国家医疗服务体系）在2012年在苏格兰地区开始此临床研究
- 全球最大的用血液标志物进行肺癌筛查的研究
- 旨在得出该手段成本筛查收益在欧洲人种的分析数据
- 旨在得出是否能降低死亡率（将跟踪超过6年）
- 总病例：10,000人（肺癌高危人群），2015年在第16届世界肺癌大会（WCLC）公布了令人兴奋的第一阶段成果：
- 第一阶段结果：特异性91%，敏感性81%
- 筛查成本与获益分析会在第二阶段公布
September 7, 2015 International Association for the Study of Lung Cancer (IAECLSSLC）， Progress with an RCT of the Detection of Autoantibodies to Tumour Antigens in Lung Cancer Using the EarlyCDT-Lung Test in Scotland (ECLS）
The ECLS Study (2012-2018)
大事记
起源于英国政府主导的国际性肺癌筛查项目
Go International
英国国家医疗服务体系(NHS) 项目启动
(2012)
第16届世界肺癌大会（WCLC）发布第一阶段成果10000人的自身抗体筛查结果
(2015)
增加筛查人群样本数,总样本将达到12000人
(2016)
开展筛查成本与获益分析研究
形成最终总体结论性报告(2016-2019)
里程碑:全球最大规模肺癌自身抗体谱性筛查报告发布(Milestone history)
(2018-2019)
相关文献Literature
1. Jemal A, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96.
2. Jungbluth AA, et al. (2000) Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 83(4):493-497.
3.Hirohashi Y, et al. (2009) The functioning antigens: beyond just as the immunological targets. Cancer Sci 100(5):798-806.
4.Rudin CM, et al. (2012) Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44(10):1111-1116.
5.Maddison P, Thorpe A, Silcocks P, Robertson JF, & Chapman CJ (2010) Autoimmunity to SOX2, clinical phenotype and survival in patients with small-
6.Giaccia AJ & Kastan MB (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12(19):2973-2983.
7.Lowe FJ, et al. (2014) A novel autoantibody test for the detection of pre-neoplastic lung lesions. Mol Cancer 13:78.
8.Gure AO, et al. (2000) Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 97(8):4198-4203.
9.Wu M, Mao C, Chen Q, Cu XW, & Zhang WS (2010) Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol Biol Rep 37(1):339-343.
10.Mack U, Ukena D, Montenarh M, & Sybrecht GW (2000) Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 7(3):669-674.
11.Shimada H, Ochiai T, & Nomura F (2003) Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97(3):682-689.
12.Gjerstorff MF, Pohl M, Olsen KE, & Ditzel HJ (2013) Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer 13:466.
13.Hibi K, et al. (1999) PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 155(3):711-715.
14.Park Y, Kim Y, Lee JH, Lee EY, & Kim HS (2011) Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. Arch Pathol Lab Med 135(12):1570-1575.
15.Murray A, et al. (2010) Technical validation of an autoantibody test for lung cancer. Ann Oncol 21(8):1687-1693.
16.Lam S, et al. (2011) EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila) 4(7):1126-1134.
17.Boyle P, et al. (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22(2):383-389.
18.Sasaki H, et al. (2001) Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn J Clin Oncol 31(11):532-535.
19.Park S, et al. (2003) Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 1625(2):173-182.
20.Yanagawa N, Tamura G, Oizumi H, Endoh M, & Motoyama T (2011) MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer. Anticancer Res 31(1):171-175.
21.Matkovic B, et al. (2011) Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer
微信公众平台
